Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Pipeline Review, H2 2017 - Research and Markets

Research and Markets
Posted on: 24 Nov 17

The "T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Pipeline Review, H2 2017" report has been added to Research and Markets' offering.

'T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Pipeline Review, H2 2017'; T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) pipeline Target constitutes close to 8 molecules. Out of which approximately 8 molecules are developed by Companies.

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - CD28 is a proteins expressed on T cells. It co-stimulates signals required for T cell activation and survival. It enhances the production of IL4 and IL10 in T-cells in conjunction with TCR/CD3 ligation and CD40L co-stimulation.

The report 'T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Pipeline Review, H2 2017' outlays comprehensive information on the T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

Key Topics Covered:

  1. Introduction
  2. T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Overview
  3. T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Therapeutics Development
  4. Products under Development by Stage of Development
  5. Products under Development by Therapy Area
  6. Products under Development by Indication
  7. Products under Development by Companies
  8. T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Therapeutics Assessment
  9. Assessment by Mechanism of Action
  10. Assessment by Route of Administration
  11. Assessment by Molecule Type
  12. T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Companies Involved in Therapeutics Development
  • Atox Bio Ltd
  • Bristol-Myers Squibb Co
  • Five Prime Therapeutics Inc
  • Johnson & Johnson
  • TheraMAB LLC

For more information about this report visit https://www.researchandmarkets.com/research/rmx3jp/t_cell_specific

View source version on businesswire.com: http://www.businesswire.com/news/home/20171124005171/en/

Business Wire
www.businesswire.com

Last updated on: 24/11/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.